Publication of prospectus regarding the rights issue in Senzime and application for listing on Nasdaq First North
Uppsala, March 14, 2017. The Board of Senzime AB (publ) ("Senzime") has prepared a prospectus regarding the rights issue that was resolved at the extraordinary general meeting in Senzime on March 3, 2017. The Board of Senzime has also applied for listing on Nasdaq First North, and the first day of trading on Nasdaq First North is expected to be April 11, 2017.
Bulletin from the Extraordinary General Meeting in Senzime AB (publ) – resolution on new issue of shares
The shareholders of Senzime have at the Extraordinary General Meeting on March 3, 2017 resolved, in accordance with the board's proposal, to issue new shares with pre-emption rights for existing shareholders.
Notice of Extraordinary General Meeting in Senzime AB (publ)
The shareholders in Senzime AB (publ) reg. no. 556565-5734 (the “Company”) are hereby convened to the extraordinary general meeting at 9.30 (local time) on Friday 3 March 2017 in the premises of Advokatfirman Lindahl at Vaksalagatan 10, 753 20, Uppsala.
is planning to carry out a fully underwritten rights issue for further market launches and is taking steps toward listing at Nasdaq First North
Uppsala February 16, 2017. The Board of Senzime AB (publ) proposes that an extra general meeting resolves on a rights issue of approximately SEK 24.4 million before issue costs. The rights issue is fully underwritten by the company's principal owner. The proceeds will be used to enable the commercialization of Senzimes products and strengthen its financial position. Concurrently Senzime is planning a listing at Nasdaq First North.
Senzime signs distribution agreements for the TetraGraph
Uppsala, February 9, 2017. Senzime AB (publ) today announced that it signed exclusive distribution agreements for TetraGraph in the UK, Ireland, Australia and New Zealand.
Senzime reports initial evaluation from the clinical trial at NorthShore in Chicago, USA
Uppsala, January 23, 2017. Senzime AB (publ) reports initial feedback from the clinical trials at NorthShore University HealthSystem, Chicago, USA, a Teaching Affiliate of the University of Chicago Pritzker School of Medicine. Professor Glenn Murphy is a world-leading clinical investigator and authority in postoperative complications that result from residual neuromuscular block in patients undergoing surgery and general anesthesia. He is the lead investigator of the study that examines the clinical utility of the TetraGraph System, and compares its ease of use, reliability and precision to the TOF-Watch, the former leading neuromuscular monitor that has been discontinued from the market.
Senzime announces the nomination committee for the AGM 2017
Uppsala, January 20, 2017. Senzime announces the nomination committee for the AGM 2017.
Senzime announces that yearend report 2016 to be released February 16, 2017
Uppsala, January 20, 2017. The Board of Senzime has decided that the yearend report is to be released one week earlier than announced.
Senzime reports completion of trial
Uppsala, January 12, 2017. Senzime AB (publ) reports completion of the initial volunteer study performed at the Mayo Clinic in the USA. The study evaluated the ease of use, required set-up time, and volunteer comfort during testing using Senzime’s patient neuromonitoring system, the TetraGraph.
Senzime launches OnZurf Probe for preclinical use
Uppsala, December 19, 2016. Senzime launches OnZurf Probe for use in preclinical research. Onzurf Probe is a new generation of microdialysis probe (catheter) that allows organ-specific monitoring after surgery on organs such as the esophagus, bowel and liver. Onzurf Probe has a unique mode of attachment to the target organ, allowing easy placement of the microdialysis catheter on the surface of the organ. This non-invasive technique obviates the need for penetrating surgical instruments that can cause tissue trauma and stress during placement of the probe.